Table 2.
Demographic characteristics of patients (n = 2060)
| Male, n (%) | 1186 (57.6) |
| Mean age, years ± SD | 61 ± 15.6 |
| Mean weight, kg ± SD | 71 ± 15.2 |
| Mean height, cm ± SD | 166 ± 9.7 |
| Ethnicity, n (%) | |
| White | 1533 (74) |
| Hispanic or Latino | 53 (3) |
| Black | 29 (1) |
| Other | 38 (2) |
| Unknown | 445 (22) |
| Etiology of renal disease, n (%) | |
| Hypertension/large vessel disease | 487 (28) |
| Glomerulonephritis | 318 (19) |
| Diabetes | 351 (21) |
| Interstitial nephritis/pyelonephritis | 217 (13) |
| Polycystic kidney disease | 109 (6) |
| Sec. glomerulonephritis/vasculitis | 56 (3) |
| Other hereditary/congenital diseases | 35 (2) |
| Neoplasms/tumors | 34 (2) |
| Other | 160 (9) |
| Undefined etiology | 315 (18) |
| Prior diseases/risk factors | |
| Vascular disorders | 1397 (68) |
| Metabolism and nutrition disorders | 778 (38) |
| Cardiac disorders | 390 (19) |
| Surgical and medical procedures | 317 (15) |
| Nervous system disorders | 151 (7) |
| Gastrointestinal disorders | 110 (5) |
| Infections and infestations | 29 (1) |
| Respiratory, thoracic and mediastinal disorders | 19 (1) |
| ESA administration during screening, % | |
| Epoetin alfa | 43 |
| Epoetin beta | 38 |
| Darbepoetin alfa | 28 |
| Other | 2 |
ESA erythropoiesis-stimulating agent, SD Standard deviation